Leerink Partners downgrades Merus stock to Market Perform on Genmab deal
NegativeFinancial Markets

Leerink Partners has downgraded Merus stock to 'Market Perform' following the recent deal with Genmab. This decision reflects concerns about Merus's future performance in light of the partnership, which could impact investor confidence and stock value. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of biotech investments.
— Curated by the World Pulse Now AI Editorial System